21:56:46 Europe / Stockholm

Prenumeration

2023-05-12 08:40:00

Redeye leaves its comments on Acarix following the company’s Q1 2023 report. The report contained no significant surprises, and we largely maintain our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/